L-NIL

Research use only, not for human use.

L-NIL is a selective nitric oxide synthase (iNOS) inhibitor that reverses burn-induced activation of glycogen synthase kinase-3β in rat skeletal muscle and may slow the progression of squamous cell carcinoma lung.

L-NIL is an inducible NO synthase inhibitor, with an IC50 of 3.3 μM for miNOS.

——

Animal Model:Adult male Balb/c (20-25 g).Dosage:10 and 30?mg/kg.Administration:Intraperitoneally at the end of CLP and at 6?h after sepsis induction. Result:Led to a negligible increase in plasma NGAL compared to sham mice.Led to a significant decrease in both TLR4 and IL1β protein contents and clusterin transcript.Showed an increase in NFAT5 mRNA levels, as compared with mice treated with vehicle.Promoted a decrease in AR protein expression, as compared with animals treated with vehicle.

——

Immunology/Inflammation

NOS

NOS

——

——

53774-63-3

187.24

C8H17N3O2

>98% (HPLC)

In Vitro:?H2O : 50 mg/mL (267.04 mM; Ultrasonic) DMSO : 1 mg/mL (5.34 mM; Ultrasonic )

CC(=N)NCCCC[C@H](N)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years